Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

Posted: February 13, 2025 at 2:44 am

Ersodetug, a novel, fully human monoclonal antibody for the treatment of hyperinsulinism (HI), receives Breakthrough Therapy Designation and Orphan Drug Designation

See the rest here:
Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

Related Posts